8-KEarnings & ResultsExhibits & Filings

STRYKER CORP 8-K Report, Financial Results (Jan 25, 2011)

Filed January 25, 2011For Securities:SYK

Summary

Stryker Corporation (SYK) filed an 8-K on January 25, 2011, to report its fourth quarter and full-year 2010 financial results. The key takeaway for investors is the announcement of strong operating results, which are further detailed in an attached press release. The company also provided guidance for 2011, notably including projected adjusted diluted earnings per share that incorporate anticipated acquisition and integration-related charges from the recent purchase of Boston Scientific's Neurovascular division. The filing emphasizes the use of non-GAAP financial measures, such as "constant currency" sales and "adjusted diluted net earnings per share," to provide a more comparable view of performance by excluding items like foreign currency impacts, asset impairments, restructuring charges, and acquisition-related costs. Investors should pay close attention to these adjusted figures as they are used by management for performance evaluation and bonus calculations and are presented to offer a clearer perspective on underlying operational trends and future potential.

Key Highlights

  • 1Stryker reported its fourth quarter and full-year 2010 operating results via a press release filed with the 8-K.
  • 2The company provided projected diluted net earnings per share guidance for the year ended December 31, 2011.
  • 3Stryker highlighted its use of non-GAAP financial measures, including "constant currency" and "adjusted diluted net earnings per share."
  • 4These non-GAAP measures are used by management for operational review, trend analysis, and bonus calculations.
  • 5The filing details that acquisition and integration-related charges are expected in 2011 due to the acquisition of assets from Boston Scientific's Neurovascular division.
  • 6Adjusted diluted EPS guidance for 2011 ranges from $3.65 to $3.73, excluding acquisition and integration charges.
  • 7The company encourages investors to review its full GAAP financial statements alongside these non-GAAP measures.

Frequently Asked Questions

The 8-K filing does not contain the specific Q4 and FY 2010 results within the document itself. Instead, it references a press release filed as Exhibit 99.1, which contains the detailed financial results. Investors would need to consult that press release for the exact figures.

These are non-GAAP financial measures used by Stryker to provide a more comparable view of their performance. 'Constant currency' removes the impact of foreign exchange rate fluctuations on sales, while 'adjusted diluted net earnings per share' excludes items like acquisition/integration costs, asset sales gains, repatriation tax impacts, impairments, and restructuring charges that can distort period-to-period comparisons. Management uses these measures for internal analysis and bonus determination.

Stryker expects to incur acquisition and integration-related charges in 2011 as a result of completing the acquisition of the assets of Boston Scientific Corporation's Neurovascular division on January 3, 2011. These expected charges are factored into their adjusted diluted earnings per share projections for 2011.

For the year ended December 31, 2011, Stryker projects adjusted diluted earnings per share to be in the range of $3.65 to $3.73. This projection excludes anticipated acquisition and integration-related charges.